Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from BerGenBio ASA ( (BRRGF) ).
BerGenBio ASA announced a delay in the timeline for its planned merger with Oncoinvent ASA and BerGenBio Norge AS, as well as the associated rights issue. The merger is expected to be completed by the end of October 2025, with trading of the combined company’s shares commencing shortly thereafter. The rights issue, which offers preferential subscription rights to existing shareholders, is anticipated to start in mid-November 2025. These developments are crucial for BerGenBio’s strategic growth, potentially enhancing its market position and providing new opportunities for stakeholders.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
BerGenBio ASA operates in the biotechnology industry, focusing on developing innovative therapies for aggressive diseases, particularly cancer. The company is engaged in research and development to bring new treatments to market, often collaborating with other entities to enhance its offerings.
Average Trading Volume: 201,797
Current Market Cap: NOK43.93M
Learn more about BRRGF stock on TipRanks’ Stock Analysis page.